Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights

Clinical Drug Investigation

Volumn 33, Issue 9, 2013, Pages 621-631

  Vallarino, Carlos ^a   Perez, Alfonso ^a   Fusco, Gregory ^a   Liang, Huifang ^a   Bron, Morgan ^b   Manne, Sudhakar ^a   Joseph, Guiandre ^a   Yu, Shawn ^b  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Takeda Pharmaceuticals International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; FLUORIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; LITHIUM; MEGLITINIDE; METFORMIN; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE DERIVATIVE; PIOGLITAZONE; PROTON PUMP INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; DATA BASE; DIABETIC PATIENT; DIURETIC THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRACTURE; HAZARD RATIO; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84883223326     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0106-9     Document Type: Article

References (44)

1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73-8.
2. Seshasai SR, Kaptoge S, Thomson A, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose, and risk of cause-specific death. New Engl J Med. 2011;364(9):829-41.
3. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl. 2001;121:13-8.
4. Goldberg RB, Kendall DM, Deeg MA, et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547-54.
5. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30(10):2458-64.
6. Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf. 2007;16(10):1065-71.
7. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89.
8. Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab. 2012;14:1-4.
9. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771(8):1065-81.
10. Dai Y, Qiao L, Chan KW, et al. Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of embelin on colon carcinogenesis. Cancer Res. 2009;69(11):4776-83.
11. Ferrara A, Lewis JD, Quesenberry CP, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34(4):923-9.
12. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254-8.
13. Takeda Pharmaceuticals America, Inc. Actos (pioglitazone hydrochloride) tablets: US prescribing information. Deerfield; 2012.
14. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-22.
15. Takeda R&D. Cohort study of pioglitazone and bladder cancer in patients with diabetes: fourth interim analysis (8-year) report, 2012. http://general.takedapharm.com/Trial-Disclosure/01-03-TL-OPI-524-8-year-Interim- Report.pdf. Accessed 17 July 2013.
16. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55(7):1953-62.
17. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645.
18. Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Pharmacol. 2013;75(1)254-9.
19. Observational Medical Outcomes Partnership. Observational Medical Outcomes Partnership 2011 symposium presentations. http://omop.fnih.org/ OMOP2011Symposium. Accessed 30 Jul 2012.
20. Garber AJ, Abrahamson AJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract. 2013;19(2):327-36.
21. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
22. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150(4):327-33.
23. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14(16):680-6.
24. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-60.
25. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561-70.
26. Choma NN, Griffin MR, Huang RL, et al. An algorithm to identify incident myocardial infarction using Medicaid data. Pharmacoepidemiol Drug Saf. 2009;18(11):1064-71.
27. Roumie CL, Mitchel E, Gideon PS, et al. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf. 2008;17(1):20-6.
28. Lin D, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80(3):557-72.
29. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
30. Surveillance Epidemiology and End Results, National Cancer Institute. Fast stats, 2010. http://seer.cancer.gov/faststats/. Accessed 10 Apr 2012.
31. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207-21.
32. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. New Engl J Med. 2012;367(4):319-28.
33. Lightwood JM, Glantz SA. Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation. 2009;120(14):1373-9.
34. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. New Engl J Med. 2010;362(23):2155-65.
35. Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J. 2011;161(1):210.e1-219.e1.
36. Forsén L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord Trøndelag Health Survey. Diabetologia. 1999;42(8):920-5.
37. Nicodemus KK, Folsom AR, Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24(7):1192-7.
38. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32-8.
39. Carnevale V, Romagnoli E, D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev. 2004;20(3):196-204.
40. de Liefde II, van der Klift M, de Laet CE, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16(12):1713-20.
41. Janghorbani M, Feskanich D, Willett WC, et al. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care. 2006;29(7):1573-8.
42. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother. 2007;41(12):2014-8.
43. Douglas IJ, Evans SJ, Pocock S, et al. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.
44. Aubert RE, Herrera V, Chen W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12(8):716-21.